Anagenics Limited
Anagenics Limited
- P/E ratio
- 15.00
Your view on AN1.AX
Overview
What the company does, where it operates, and who runs it.
About Anagenics Limited
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- CEO
- Chris Lewis
- Headquarters
- 68 Pitt Street, Sydney, NSW, AU
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- CEO
- Chris Lewis
- Headquarters
- 68 Pitt Street, Sydney, NSW, AU
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name.
It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021.
Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Anagenics Limited. Starting points for Anagenics Limited: P/E 15.0, beta 0.44 — an Household & Personal Products name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Anagenics Limited. Anagenics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Anagenics Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2018 | Next yearYear to Jun 2019 |
|---|---|---|
| Average estimate | −AUD 0.06 | −AUD 0.02 |
| Lowest estimate | −AUD 0.06 | −AUD 0.02 |
| Highest estimate | −AUD 0.06 | −AUD 0.02 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Revenue estimates
| Total | This yearYear to Jun 2018 | Next yearYear to Jun 2019 |
|---|---|---|
| Average estimate | AUD 5.60M | AUD 10.00M |
| Lowest estimate | AUD 5.60M | AUD 10.00M |
| Highest estimate | AUD 5.60M | AUD 10.00M |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Anagenics Limited. Anagenics Limited has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ASP.AXAspermont Limited | Communication Services | Publishing | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ATX.AXAmplia Therapeutics Limited | Healthcare | Biotechnology | — | ||
| BLS.AXBLS Pharmaceuticals Limited | Industrials | Specialty Business Services | — | ||
| ELThe Estée Lauder Companies Inc. | Consumer Defensive | Household & Personal Products | $37.7B | ||
| NWLNewell Brands Inc. | Consumer Defensive | Household & Personal Products | $2.4B | ||
| PGThe Procter & Gamble Company | Consumer Defensive | Household & Personal Products | $394.7B | ||
| RBGLYReckitt Benckiser Group plc | Consumer Defensive | Household & Personal Products | $58.1B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| KCDMFKimberly-Clark de México, S. A. B. de C. V. | Consumer Defensive | OTC | $7.9B | ||
| KCDMYKimberly-Clark de México, S. A. B. de C. V. | Consumer Defensive | OTC | $7.5B | ||
| KITAFKitanotatsujin Corporation | Consumer Defensive | OTC | $135.3M | ||
| KMBKimberly-Clark Corporation | Consumer Defensive | NASDAQ | $35.7B | ||
| KOSCFKOSÉ Corporation | Consumer Defensive | OTC | $1.9B | ||
| KPOCKimberly Parry Organics Inc. | Consumer Defensive | OTC | $1.4M | ||
| KPT.TOKP Tissue Inc. | Consumer Defensive | TSX | $123.8M | ||
| KPTSFKP Tissue Inc. | Consumer Defensive | OTC | $80.1M | ||
| KSRYYKOSÉ Corporation | Consumer Defensive | OTC | $2.2B | ||
| KVUEKenvue Inc. | Consumer Defensive | NYSE | $37.1B | ||
| LIOPFLion Corporation | Consumer Defensive | OTC | $3.2B | ||
| LIOPYLion Corporation | Consumer Defensive | OTC | $2.3B | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Anagenics Limited.